LLY vs ZBH
By Alex · Tickerpine
Eli Lilly and Company vs Zimmer Biomet Holdings, Inc., side by side — the numbers that matter, in plain English. No “winner” hype; you decide.
| Metric | LLY | ZBH |
|---|---|---|
| Price | $1,233.66 | $100.24 |
| Market cap | $1.10T | $19.12B |
| P/E ratio | 41.8 | 24.5 |
| ROE | 102.29% | 6.41% |
| Profit margin | 33.53% | 9.48% |
| Revenue growth | 47.70% | 4.80% |
| Dividend yield | 0.55% | 0.95% |
| Beta | 0.51 | 0.46 |
Green = the more favorable figure for that metric (lower P/E, higher ROE, margin, growth and yield). Not a recommendation.
LLY vs ZBH in plain English
- LLY is the bigger company — about 57.5× the market cap of ZBH.
- ZBH is cheaper on earnings (P/E 24.5 vs 41.8).
- LLY earns a higher return on equity (102% vs 6%).
- LLY is growing revenue faster (48% vs 5%).
- ZBH has the higher dividend yield (0.95% vs 0.55%).
How would $1,000 have done in each?
LLY return calculator
See what $1,000 in Eli Lilly and Company would be worth today.
ZBH return calculator
See what $1,000 in Zimmer Biomet Holdings, Inc. would be worth today.
Figures from public market data, may be delayed. Comparison is informational only — not investment advice.